Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Director | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02 | Direct | 90,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: This grant vests in full upon the earlier of (i) June 10, 2026 and (ii) the date of the next annual meeting of the Company's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant vests in full upon the earlier of (i) June 10, 2026 and (ii) the date of the next annual meeting of the Company's stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 16:32 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001171843-26-000052 · ownership.xml · derivative · entry 1 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: This grant vests in full upon the earlier of (i) June 10, 2026 and (ii) the date of the next annual meeting of the Company's stockholders. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 17:10 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001171843-25-000827 · ownership.xml · derivative · entry 1 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 11, 2025. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 12:00 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001171843-24-000792 · ownership.xml · derivative · entry 1 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 9, 2024. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 16:28 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001171843-23-000853 · ownership.xml · derivative · entry 1 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-02-07 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 8, 2023. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 17:45 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000899243-22-007426 · doc4.xml · derivative · entry 1 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in substantially equal monthly installments over four years. F2 · ownership.direct: The Reporting Person is a managing partner of Borealis Ventures. Pursuant to an agreement with Borealis Ventures, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Borealis Granite Fund, L.P. and Vox Health Fund, L.P. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:37 UTC | Compass Therapeutics, Inc. NONE · Entity 5614 | PurchaseCommon Stock | 250,000 | $5.00 | $1,250,000.00 |
DisclosureSEC source: 0001213900-20-015637 · ownership.xml · nonDerivative · entry 2 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 400,280 F2 · ownership.nature: These shares are held directly by Vox Health Fund, L.P. Borealis Capital Partners IV, LLC is the general partner of Vox Health Fund, L.P. Philip Ferneau, a member of the board of directors, and a managing partner of Borealis Ventures. Mr. Ferneau holds a majority ownership interest in Borealis Capital Partners IV, LLC and is the designated manager with voting and investment power over the shares held by Vox Health Fund, L.P. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:37 UTC | Compass Therapeutics, Inc. NONE · Entity 5614 | PurchaseCommon Stock | 64,066 | $5.00 | $320,330.00 |
DisclosureSEC source: 0001213900-20-015637 · ownership.xml · nonDerivative · entry 1 Ferneau Philip · CIK 0001814202 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,348,976 F1 · ownership.nature: These shares are held directly by Borealis Granite Fund, L.P. Borealis Capital Partners III, LLC is the general partner of Borealis Granite Fund, L.P. The Reporting Person is a member of the board of directors, and is a managing partner of Borealis Ventures. Voting and investment decisions with respect to the securities held by Borealis Granite Fund, L.P. are made by a committee of three or more individuals, none of whom individually has the power to direct such decisions. The Reporting Person disclaims beneficial ownership of the shares held by Borealis Granite Fund, L.P., except to the extent of any actual pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.